

New Operations Vice President for Q-Med

- **Claes Mörlin replaces Bengt Ågerup as Vice President of Q-Med Operations, comprising the departments of R&D, Clinical Research, Production and Regulatory Affairs.**
- **Bengt Ågerup will focus on Q-Med's exploratory research, in particular within the framework of the newly started fourth business area, Cell Therapy and Encapsulation.**

On August 21, Claes Mörlin took on the role of Vice President of Operations within Q-Med, a unit which comprises research and development, clinical research, production and regulatory affairs. He succeeds Q-Med's founder, Bengt Ågerup.

Claes is a medical doctor and an Associate Professor in internal medicine and he has previously worked, amongst other things, at the University Hospital in Uppsala, MSD and Bristol-Myers Squibb. His most recent post was at Pharmacia.

Bengt Ågerup will take on a freer role within Q-Med, with responsibility for Q-Med's exploratory research. Bengt will be responsible for Q-Med's newly established fourth business area, Cell Therapy and Encapsulation. Today the business area includes 59% of the American biotechnology company, Ixion Biotechnology, Inc. Ixion carries out research around the culture and transplantation of insulin-producing islet cells with a view to treating diabetes as well as the diagnosis and treatment of oxalate-related diseases.

There is also collaboration within the cell therapy area with Karolinska Institute, where Bengt Ågerup is a member of the Board of the Center for Medical Innovations.

September 1, 2000

Uppsala, Sweden

Q-Med AB (publ)

Per Olof Wallström

President and CEO

Queries should be addressed to Per Olof Wallström, President and CEO, on +46(0)18-474 90 00 or +46(0)70-974 90 70.

Q-Med is a rapidly growing and profitable biotechnology and medical device company that develops, produces and markets non-animal hyaluronic acid based medical implants. All products are based on the company's patented technology for the production of NASHA - Non-Animal Stabilized Hyaluronic Acid. Q-Med's operations focus on the areas of Esthetics, Orthopedics, Uro-Gynecology and Cell Therapy and Encapsulation. Esthetics contains the products RESTYLANE, RESTYLANE FINE LINES and PERLANE for facial esthetics. RESTYLANE, for the correction of facial wrinkles and lip enhancement, today accounts for the majority of sales. The development of MACROLANE for breast augmentation is ongoing. Orthopedics is responsible for DUROLANE, the product for the treatment of osteoarthritis in the knee-joint which is under development. Uro-Gynecology contains DEFLUX for vesicoureteral reflux (malformation of the urinary bladder) in children and stress urinary incontinence in women. Cell Therapy and Encapsulation holds 59% of the American biotechnology company Ixion Biotechnology, Inc., with business operations within cell therapy for diabetes. Q-Med today has 160 employees, with 110 at Q-Med's production facility and head office in Uppsala, 10 at Ixion and the remainder in wholly owned foreign subsidiaries. The Q-Med share has been listed on the O-list of the OM Stockholm Stock Exchange since December 6, 1999.